Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Apr 24
8-K
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
12 Apr 24
8-K
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
11 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Regulation FD Disclosure
23 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Oncocyte Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K/A
Changes in Registrant's Certifying Accountant
10 Oct 23
8-K
Changes in Registrant's Certifying Accountant
5 Oct 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
8-K
Other Events
28 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Oncocyte Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
ONCOCYTE ANNOUNCES 1-for-20 reverse stock split
24 Jul 23
DEFA14A
Additional proxy soliciting materials
21 Jul 23
8-K
Departure of Directors or Certain Officers
14 Jul 23
DEF 14A
Definitive proxy
10 Jul 23
PRE 14A
Preliminary proxy
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
8-K
Departure of Directors or Certain Officers
8 Jun 23
8-K
Regulation FD Disclosure
6 Jun 23
DEFR14A
Revised proxy
22 May 23
DEF 14A
Definitive proxy
19 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Oncocyte Reports First Quarter 2023 Financial Results
11 May 23
8-K
Oncocyte Announces Reduction in Force
13 Apr 23
10-K
2022 FY
Annual report
12 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
424B5
Prospectus supplement for primary offering
5 Apr 23
8-K
Results of Operations and Financial Condition
5 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
ONCOCYTE REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS and PLANS TO FILE FORM 12b-25 to extend filing date of its form 10-k
31 Mar 23
8-K
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
2 Mar 23
8-K
Entry into a Material Definitive Agreement
23 Feb 23
8-K/A
Submission of Matters to a Vote of Security Holders
17 Feb 23
8-K
Entry into a Material Definitive Agreement
13 Feb 23
8-K
Entry into a Material Definitive Agreement
3 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jan 23
8-K
Oncocyte Announces Initiatives to Focus Corporate Strategy
21 Dec 22
Latest ownership filings
SC 13D/A
BROADWOOD PARTNERS, L.P.
15 Apr 24
4
NEAL C BRADSHER
15 Apr 24
4
Josh Riggs
15 Apr 24
4
Andrew Arno
15 Apr 24
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Feb 24
SC 13G/A
AWM Investment Company, Inc.
14 Feb 24
4
James Yang Liu
12 Oct 23
4
Josh Riggs
17 Aug 23
4
John Peter Gutfreund
3 Jul 23
4
Andrew Arno
27 Jun 23
4
Andrew J. Last
27 Jun 23
4
ALFRED D KINGSLEY
27 Jun 23
4
LOU SILVERMAN
27 Jun 23
4
ALFRED D KINGSLEY
15 Jun 23
4
Josh Riggs
13 Jun 23
4
Efrem Kamen
18 Apr 23
4/A
Efrem Kamen
18 Apr 23
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Apr 23
4
Efrem Kamen
7 Apr 23
SC 13D/A
BROADWOOD PARTNERS, L.P.
7 Apr 23
4
NEAL C BRADSHER
5 Apr 23
4
John Peter Gutfreund
5 Apr 23
4
Andrew Arno
5 Apr 23
4
Efrem Kamen
8 Mar 23
4
Josh Riggs
28 Feb 23
4
Anish M. John
28 Feb 23
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Feb 23
SC 13G
PURA VIDA INVESTMENTS, LLC
14 Feb 23
SC 13G
AWM Investment Company, Inc.
14 Feb 23
4
Josh Riggs
19 Jan 23
4
James Yang Liu
19 Jan 23
4
Anish M. John
19 Jan 23
4
Andrew Arno
28 Dec 22
4
John Peter Gutfreund
28 Dec 22
4
ALFRED D KINGSLEY
27 Dec 22
4
Douglas T. Ross
22 Dec 22
4
Douglas T. Ross
20 Dec 22
4
Gisela Paulsen
20 Dec 22
4
RONALD ASBURY ANDREWS
9 Dec 22
3
LOU SILVERMAN
9 Dec 22